Truist analyst Srikripa Devarakonda lowered the firm’s price target on Affimed to $8 from $12 and keeps a Buy rating on the shares after the company reported two "key data sets" – including pivotal r/r PTCL and updated cbNK/AFM13 combo MDACC collab data – at ASH over the weekend. The analyst anticipates pressure on stock due to pushed-out timelines for its first commercial asset, but believes the company is pursuing the right development strategy and reiterates conviction in its platform.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AFMD:
- Affimed Plunges after Detailing New Plans
- Affimed presents updated data from AFM28
- Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting
- Affimed initiated with a Buy at H.C. Wainwright
- Piper Sandler keeps Overweight rating on Affimed, lowers price target to $6
